Lido Advisors’s Maravai LifeSciences MRVI Stock Holding History

Lido Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-20,146	Closed	-$718K	–	934
2021 Q1	$718K	Buy	+20,146	New	+$667K	0.01%	415

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Lido Advisors's MRVI Position: Q2 2021 in Review

Lido Advisors sold out of Maravai LifeSciences (MRVI) in Q2 2021, closing a stake of 20,146 shares — an estimated $718K sold.

Lido Advisors first reported a position in MRVI in Q1 2021 and held it in 1 quarter. The position peaked at $718K in Q1 2021. 196 funds tracked by Wall St. Rank hold MRVI as of Q2 2021.

Lido Advisors reported no remaining Maravai LifeSciences position as of Q2 2021 after selling out during the quarter.
Lido Advisors sold 20,146 Maravai LifeSciences shares in Q2 2021, an estimated $718K.
Lido Advisors first reported a position in Maravai LifeSciences in Q1 2021 and held it in 1 quarter.
Lido Advisors's Maravai LifeSciences position peaked at $718K in Q1 2021.
196 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2021.

Based on Lido Advisors's 13F filing for Q2 2021, filed 12 Aug 2021.